# Comparables

---
Type: page
Date: 2026-01-03
---

# M&A Comparable Transactions: Executive Summary

## Dimer Health Valuation Context

**Prepared:** January 2026
**Subject Company:** Dimer Health - Virtual Transitional Care Platform

---

## Overview

This analysis examines 16 M&A transactions relevant to Dimer Health's positioning as a virtual transitional care company focused on reducing hospital readmissions through AI-powered, physician-led post-discharge care. The comparables span five exit scenario archetypes:

| Exit Scenario | Typical Buyers | Multiple Range | Key Examples |
|---------------|----------------|----------------|--------------|
| Payer Vertical Integration | Humana, UnitedHealth/Optum, CVS | 2-3x revenue, 10-20x EBITDA | Kindred at Home, LHC Group, Signify Health |
| Platform/Software Exit | Digital health platforms, Big Tech | 10-15x revenue | Nuance-Microsoft, Livongo-Teladoc |
| Retail Healthcare Roll-Up | Walgreens, CVS | 0.5-2x revenue | CareCentrix |
| PE Platform Combination | Berkshire, Clearlake, TPG | 5-10x revenue (estimated) | Medalogix+Forcura, PatientPing |
| Distressed/Acqui-hire | Strategic platforms | 2-5x revenue | 98point6, Augmedix |

---

## Transaction Summary

| Target | Acquirer | Year | Deal Value | Revenue | Multiple | Exit Type |
|--------|----------|------|------------|---------|----------|-----------|
| **Kindred at Home** | Humana | 2021 | $8.1B | $3.0B | **2.7x** | Payer Integration |
| **LHC Group** | Optum | 2023 | $5.4B | $2.5B | **2.2x / 19x EBITDA** | Payer Integration |
| **Nuance** | Microsoft | 2022 | $19.7B | $1.5B | **13x** | Big Tech Platform |
| **Collective Medical** | PointClickCare | 2020 | $650M | N/D | ~14x capital | EHR Platform |
| **CareCentrix** | Walgreens | 2022 | $722M | $1.5B | **0.48x** | Retail Roll-Up |
| **PatientPing** | Appriss/Bamboo | 2021 | ~$500M | N/D | ~5x capital | PE Roll-Up |
| **Medalogix+Forcura** | Berkshire | 2025 | ~$1.0B | N/D | N/A | PE Platform |
| **Augmedix** | Commure | 2024 | $139M | $51M ARR | **2.7x** | Platform Roll-Up |
| **98point6** | Transcarent | 2023 | $100M | ~$25M | **~4x** | Distressed |
| **Care.ai** | Stryker | 2024 | Undisclosed | ~$17M | Est. 5-15x | MedTech Platform |
| **InTouch Health** | Teladoc | 2020 | $600M | ~$60M | **~10x** | Telehealth Platform |
| **Conversa Health** | Amwell | 2021 | $320M | N/D | Est. 10-15x | Telehealth Platform |
| **BioTelemetry** | Philips | 2021 | $2.8B | $465M | **6x** | MedTech Platform |
| **Lumeon** | Health Catalyst | 2024 | $47M | N/D | N/A | Analytics Platform |
| **ScienceIO** | Veradigm | 2024 | ~$15M | N/D | N/A | Data Platform |
| **Watson Health** | Francisco Partners | 2022 | ~$1B | N/D | N/A | PE Carve-out |

---

## Comparable Transaction Profiles

### 1. Kindred at Home → Humana (2021) | $8.1B | 2.7x Revenue
**Exit Type:** Payer Vertical Integration

Humana acquired the nation's largest home health and hospice provider to own post-acute care delivery infrastructure for its Medicare Advantage members. This was a two-stage deal—Humana first invested 40% in 2018, proved the model over 3 years (growing member penetration from 8% to 19%), then acquired the remaining 60%. The "test before you buy" approach validated outcomes including reduced hospitalizations, readmissions, and ER utilization. Post-acquisition, the home health business was rebranded to CenterWell Home Health while hospice was divested to CD&R. This deal triggered an industry-wide payer consolidation race that continues today.

**Dimer Relevance:** Validates payer appetite for care transition capabilities; Humana explicitly cited readmission reduction outcomes as decision factors—directly comparable to Dimer's 67% readmission reduction.

---

### 2. LHC Group → Optum/UnitedHealth (2023) | $5.4B | 2.2x Revenue, 19x EBITDA
**Exit Type:** Payer Vertical Integration

UnitedHealth's Optum acquired LHC Group as a competitive response to Humana's Kindred acquisition. The deal added 30,000 employees, 527 home health locations, and 435+ hospital partnerships—the latter being a critical referral infrastructure asset. LHC's quality scores ran "more than one-third higher than industry norms," which Optum explicitly cited as a value driver. The 19x EBITDA multiple reflects the strategic premium for quality, scale, and hospital relationships. Notably, the FTC scrutinized worker pay practices but ultimately did not block the deal. UnitedHealth subsequently bid $3.3B for Amedisys, showing continued home health appetite.

**Dimer Relevance:** Premium valuations for quality (LHC's scores above industry norms parallel Dimer's 67% readmission reduction); hospital partnership value (LHC's 435 relationships comparable to Dimer's Atlantic, Bergen, RWJBarnabas partnerships).

---

### 3. CareCentrix → Walgreens (2022) | $722M | 0.48x Revenue
**Exit Type:** Retail Healthcare Platform Roll-Up

Walgreens acquired this post-acute care benefit management platform as part of its transformation into an integrated healthcare company. At 0.48x revenue, the deal was remarkably cheap compared to clinical care delivery acquisitions. The key distinction: CareCentrix operates as an intermediary/coordinator managing 19M+ members across 7,400+ provider locations, rather than delivering clinical care directly. This suggests **benefit management platforms command significantly lower multiples than clinical care delivery.** The deal also reflected distressed seller dynamics—Summit Partners had held since 2011 and tried to exit since 2015. Walgreens' broader healthcare investments have since faced challenges, with 2024 reports of potential divestitures.

**Dimer Relevance:** As a clinical care delivery company (not benefit management), Dimer should command higher multiples than CareCentrix; validates retail buyer interest in care transitions capabilities.

---

### 4. Nuance Communications → Microsoft (2022) | $19.7B | 13x Revenue
**Exit Type:** Big Tech Platform Play

Microsoft's largest healthcare acquisition positioned Azure as the dominant cloud platform for healthcare by controlling the AI applications that drive adoption. Nuance had 77% U.S. hospital penetration and pioneered ambient clinical documentation (Dragon Medical). CEO Satya Nadella framed it explicitly as an AI acquisition: "AI is technology's most important priority, and healthcare is its most urgent application." The deal closed despite extended UK CMA review, validating regulatory pathways for healthcare AI acquisitions. Post-acquisition, Microsoft launched DAX Copilot (AI ambient scribe) as a flagship product.

**Dimer Relevance:** Validates premium valuations for healthcare AI capabilities; Dimer's AiME AI companion is analogous to Nuance's clinical AI, though at earlier stage; suggests Big Tech could be acquirer category for AI-first healthcare companies.

---

### 5. Collective Medical → PointClickCare (2020) | $650M | ~14x Return on Capital
**Exit Type:** Strategic Platform Acquisition

PointClickCare (dominant post-acute EHR) acquired the leading real-time care coordination and ADT notification network to create the "largest combined acute and post-acute care network." Collective Medical was exceptionally capital efficient—bootstrapped for 8 years before taking $47.5M in Series A funding, then exited at $650M. The CMS e-notifications mandate created guaranteed demand for their solution. COVID-19 highlighted care transition gaps, accelerating buyer interest.

**Dimer Relevance:** Highest-relevance comparable for Dimer's care transitions mission; regulatory tailwinds (CMS readmission penalties) parallel; demonstrates value of network effects in care coordination.

---

### 6. PatientPing → Appriss Health/Bamboo (2021) | ~$500M | ~5x Return on Capital
**Exit Type:** PE Platform Roll-Up

PE-backed Appriss Health acquired the dominant ADT notification platform to create Bamboo Health, the largest real-time care collaboration network in the US. PatientPing processed 135M ADT events annually across 1,000+ hospitals and 5,000+ post-acute facilities. The deal combined behavioral health analytics (Appriss) with physical health care coordination (PatientPing) for a "whole-person care" platform.

**Dimer Relevance:** PatientPing solved the same care transitions problem Dimer addresses; PE buyers demonstrated appetite for care coordination infrastructure; CMS mandates created demand floor.

---

### 7. Medalogix + Forcura → Berkshire Partners/Mosai (2025) | ~$1B Combined
**Exit Type:** PE Platform Combination

Berkshire Partners orchestrated a merger of Medalogix (predictive analytics for home health) with Forcura (intelligent workflow management) to create a ~$1B "referral to discharge" platform for post-acute care. The combined entity rebranded to Mosai within 7 months, signaling aggressive integration. Both companies previously had different PE backers (Vistria, Accel-KKR), demonstrating PE sponsor willingness to combine complementary assets.

**Dimer Relevance:** Validates ~$1B valuations for scaled post-acute care technology platforms; predictive analytics and care optimization capabilities align with Dimer's AI-powered approach.

---

### 8. 98point6 → Transcarent (2023) | $100M | ~4x Revenue
**Exit Type:** Distressed Platform Acquisition

Transcarent (led by Livongo co-founder Glen Tullman) acquired 98point6's AI-powered virtual care platform for $100M after the company raised $247M total—representing significant value destruction. 98point6 was "losing 60 cents for every dollar of revenue" despite strong technology. The deal was structured as a partial acquisition; 98point6 retained its technology licensing business. This demonstrates that **technology alone doesn't command premium valuations; unit economics and profitability path matter.**

**Dimer Relevance:** Cautionary tale—AI-enabled telehealth with poor unit economics struggles despite strong technology; validates importance of Dimer's sustainable model with health system/payer contracts.

---

### 9. Augmedix → Commure (2024) | $139M | 2.7x ARR
**Exit Type:** Healthcare Platform Roll-Up

Commure (backed by General Catalyst, previously merged with Athelas at $6B valuation) acquired Augmedix's ambient AI documentation at a modest 2.7x revenue despite 45% growth and 152% net revenue retention. The deal was a take-private transaction that freed Augmedix from public market pressures. Commure positioned the combination as creating "the largest artificial intelligence software provider in healthcare."

**Dimer Relevance:** Shows healthcare AI platforms consolidating; 2.7x revenue for high-growth AI company reflects 2024 market correction; validates Commure/General Catalyst as acquirer category.

---

### 10. Care.ai → Stryker (2024) | Undisclosed | Est. 5-15x
**Exit Type:** MedTech Platform Integration

Stryker acquired this AI-powered virtual nursing and ambient intelligence platform to extend its Vocera communication platform with AI capabilities. Care.ai combines proprietary hardware (sensors) with AI software to create "smart patient rooms" addressing nursing shortages. The deal was undisclosed despite Care.ai raising $27M Series B just 18 months prior, suggesting either strategic premium or more modest multiple.

**Dimer Relevance:** Validates MedTech companies as acquirer category for healthcare AI; Care.ai's virtual nursing/ambient AI addresses similar clinical workflow challenges as Dimer's Transitionist model.

---

### 11. InTouch Health → Teladoc (2020) | $600M | ~10x Revenue
**Exit Type:** Telehealth Platform Consolidation

Teladoc acquired InTouch Health's enterprise telehealth platform to expand beyond consumer telehealth into hospital and health system markets. InTouch was deployed in 450+ hospitals with deep integrations. The deal preceded the COVID-19 surge, after which virtual care valuations spiked dramatically (setting stage for the Livongo deal).

**Dimer Relevance:** Enterprise health system telehealth commands ~10x revenue; Dimer's B2B health system model aligns with InTouch's positioning.

---

### 12. Conversa Health → Amwell (2021) | $320M | Est. 10-15x
**Exit Type:** Telehealth Platform Consolidation

Amwell acquired Conversa's conversational AI platform for patient engagement during the peak of COVID-driven telehealth valuations. The deal added automated patient outreach and engagement capabilities to Amwell's virtual care platform.

**Dimer Relevance:** AI-powered patient engagement valued at 10-15x revenue at market peak; Dimer's AiME AI companion provides similar capabilities.

---

### 13. BioTelemetry → Philips (2021) | $2.8B | 6x Revenue
**Exit Type:** MedTech Platform Integration

Philips acquired BioTelemetry's remote patient monitoring capabilities to extend its connected care and informatics businesses. The deal combined hardware (monitoring devices) with AI-powered analytics for cardiac and other conditions.

**Dimer Relevance:** Remote monitoring + AI analytics for chronic conditions valued at 6x revenue; demonstrates MedTech appetite for digital health capabilities.

---

### 14. Lumeon → Health Catalyst (2024) | $47M
**Exit Type:** Analytics Platform Consolidation

Health Catalyst acquired Lumeon's care journey orchestration platform to add automated clinical workflow capabilities to its analytics suite. A relatively small deal reflecting compressed 2024 valuations for healthcare tech.

**Dimer Relevance:** Care pathway orchestration capabilities aligned with Dimer's transitional care workflows; demonstrates analytics company buyer category.

---

### 15. ScienceIO → Veradigm (2024) | ~$15M
**Exit Type:** Data Platform Consolidation

Veradigm acquired ScienceIO's medical NLP capabilities at a modest valuation. Small deal reflecting challenging market conditions for healthcare AI companies without significant scale.

**Dimer Relevance:** Limited relevance given size; demonstrates compressed valuations for early-stage healthcare AI without proven scale.

---

### 16. Watson Health → Francisco Partners (2022) | ~$1B
**Exit Type:** PE Carve-out

IBM sold Watson Health to Francisco Partners after years of underperformance. The deal represented a significant discount to IBM's cumulative investment but gave Francisco Partners a platform for turnaround/restructuring.

**Dimer Relevance:** Cautionary tale—even well-funded healthcare AI can struggle without product-market fit; validates PE carve-out as exit path for challenged assets.

---

## Key Findings for Dimer Health

### 1. Clinical Care Delivery Commands Premium Over Benefit Management

| Model | Example | Multiple |
|-------|---------|----------|
| Clinical care delivery (home health) | LHC Group, Kindred | 2-3x revenue, 15-20x EBITDA |
| Benefit management (intermediary) | CareCentrix | 0.5x revenue |

**Implication:** Dimer's direct clinical care delivery model (employing its own Transitionists) should command multiples closer to home health providers than benefit management platforms.

### 2. Outcomes and Quality Justify Strategic Premiums

Both LHC Group (quality scores 1/3 above industry) and Kindred at Home (documented reduced readmissions) received explicit recognition for outcomes in buyer rationales.

**Implication:** Dimer's 67% readmission reduction is a differentiated, documentable outcome that should drive premium valuations—particularly from payer buyers focused on CMS penalties and VBC performance.

### 3. Hospital Partnerships Are Valuable Assets

LHC Group's 435+ hospital partnerships were explicitly cited as strategic value. These relationships provide referral infrastructure and integration points.

**Implication:** Dimer's partnerships with Atlantic Health, Bergen New Bridge Medical Center, and RWJBarnabas Health are strategic assets that increase acquirer interest.

### 4. Payers and Retailers Are Active Acquirers

The 2020-2023 period saw aggressive vertical integration:
- Humana → Kindred at Home ($8.1B)
- UnitedHealth/Optum → LHC Group ($5.4B), naviHealth ($2.5B)
- CVS → Signify Health ($8B)
- Walgreens → CareCentrix ($722M)

**Implication:** Major payers and retail healthcare players are validated buyers for care transition capabilities.

### 5. Virtual-First Models May Command Different Multiples

Physical home health (Kindred, LHC) trades at 2-3x revenue with lower margins but massive scale. Virtual care platforms (Teladoc-era deals) traded at 10-15x at market peaks but have compressed to 3-5x in 2024.

**Implication:** Dimer's virtual-first model with AI capabilities positions between physical services and pure software; likely 5-10x revenue range depending on growth and unit economics.

### 6. Unit Economics and Path to Profitability Matter

98point6's distressed sale ($100M on $247M raised) demonstrates that AI technology without sustainable unit economics struggles. Augmedix's modest 2.7x multiple despite 45% growth reflects market scrutiny of profitability.

**Implication:** Dimer's business model sustainability and path to profitability will significantly impact valuation.

---

## Implied Valuation Framework for Dimer Health

Based on comparable transaction analysis:

| Scenario | Multiple Range | Implied Value Range* | Key Assumptions |
|----------|----------------|---------------------|-----------------|
| **Distressed/Tuck-in** | 2-4x revenue | $16M - $31M | Poor unit economics, limited differentiation |
| **Platform Roll-Up** | 5-8x revenue | $39M - $62M | PE buyer, combined with portfolio company |
| **Strategic (Payer/Retail)** | 8-12x revenue | $62M - $94M | Strategic fit, outcomes validated |
| **Premium Strategic** | 12-15x revenue | $94M - $117M | Competitive process, multiple strategic bidders |

*Based on ~$7.8M estimated revenue; ranges illustrative only

### Valuation Drivers to Monitor

**Positive Factors:**
- 67% readmission reduction (best-in-class outcomes)
- Health system partnerships (Atlantic, RWJBarnabas, Bergen)
- AI-powered platform (AiME differentiator)
- Regulatory tailwinds (CMS readmission penalties)
- Physician-led clinical model (differentiated from nurse triage)

**Risk Factors:**
- Early stage (~$7.8M revenue, ~42 employees)
- Limited geographic coverage (5 states)
- Path to profitability unverified
- Competitive market (DispatchHealth, Signify, others)

---

## Recommended Positioning

1. **Lead with outcomes:** 67% readmission reduction is the headline metric for payer buyers
2. **Emphasize clinical differentiation:** "Transitionist" specialty and physician-led model vs. commoditized telehealth
3. **Highlight AI capabilities:** AiME as technology moat and scalability enabler
4. **Demonstrate unit economics:** Path to profitability critical for current market
5. **Expand health system partnerships:** Each partnership adds strategic value for acquirer
6. **Consider payer pilot programs:** Humana's "test before buy" model suggests pilots de-risk acquisitions

---

*Analysis compiled from 16 M&A transactions researched January 2026*
*Source files: dimer/comparables/*.md*